Long-term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohort.

Abstract

APMISVolume 131, Issue S147 p. 1-46 Supplement Article Long-term disease course, cost and prognosis of inflammatory bowel disease: epidemiological studies of a European and a Danish inception cohort Johan Burisch, Corresponding Author Johan Burisch [email protected] University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this author Johan Burisch, Corresponding Author Johan Burisch [email protected] University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this author First published: 19 June 2023 https://doi.org/10.1111/apm.13334Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL REFERENCES 1Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369: 1627– 40. 2 GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020; 5: 17– 30. 3Zhao M, Gönczi L, Lakatos PL, Burisch J. The burden of inflammatory bowel disease in Europe in 2020. J Crohns Colitis. 2021; 15: 1573– 87. 4Lo B, Zhao M, Vind I, Burisch J. The risk of Extraintestinal cancer in inflammatory bowel disease: a systematic review and meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol. 2021; 19: 1117– 38.e19. 5Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106: 644– 59. 6Costa J, Magro F, Caldeira D, Alarcão J, Sousa R, Vaz-Carneiro A. Infliximab reduces hospitalizations and surgery interventions in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2013; 19: 2098– 110. 7Colombel J-F, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017; 6736: 1– 11. 8Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet. 2015; 386: 1825– 34. 9Burisch J, Pedersen N, Čuković-Čavka S, Brinar M, Kaimakliotis I, Duricova D, et al. East-west gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut. 2014; 63: 588– 97. 10Lakatos L, Lakatos PL. Management of inflammatory bowel diseases in Eastern Europe. Postgrad Med J. 2006; 82: 270– 3. 11Munkholm P, Binder V. Clinical features and natural history of Crohn's disease. In: JB Kirsner, RB Sartor, WJ Sandborn, editors. Kirsner's inflammatory bowel diseases. 6th ed. Philadelphia: Saunders; 2003: 289– 300. 12Binder V. Clinical epidemiology–how important now? Gut. 2005; 54: 574– 5. 13Ha C, Ullman TA, Siegel CA, Kornbluth A. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012; 10: 1002– 7. 14Burisch J. Crohn's disease and ulcerative colitis: occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Dan Med J. 2014; 61:B4778. 15Munkholm P. Crohn's disease–occurrence, course and prognosis. An epidemiologic cohort-study Dan Med Bull. 1997; 44: 287– 302. 16Langholz E. Ulcerative colitis. An epidemiological study based on a regional inception cohort, with special reference to disease course and prognosis. Dan Med Bull. 1999; 46: 400– 15. 17Langholz E, Munkholm P, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of ulcerative colitis in Copenhagen county from 1962 to 1987. Scand J Gastroenterol. 1991; 26: 1247– 56. 18Munkholm P, Langholz E, Nielsen OH, Kreiner S, Binder V. Incidence and prevalence of Crohn's disease in the county of Copenhagen, 1962-87: a sixfold increase in incidence. Scand J Gastroenterol. 1992; 27: 609– 14. 19Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and county, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol. 2006; 101: 1274– 82. 20Burisch J, Cukovic-Cavka S, Kaimakliotis I, Shonová O, Andersen V, Dahlerup JF, et al. Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe. An EpiCom study. J Crohn's Colitis. 2011; 5: 342– 9. 21Schmidt M, Schmidt SAJ, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015; 7: 449– 90. 22Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health. 2011; 39: 26– 9. 23Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish cancer registry–history, content, quality and use. Dan Med Bull. 1997; 44: 535– 9. 24Silverberg MS, Satsangi J, Ahmad T, Arnott IDR, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal world congress of gastroenterology. Can J Gastroenterol. 2005; 19(Suppl A): 5– 36. 25Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998; 43: 29– 32. 26Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980; 1: 514. 27Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol. 1995; 30: 699– 706. 28Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994; 107: 3– 11. 29Odes S, Vardi H, Friger M, Wolters F, Russel MG, Riis L, et al. Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006; 131: 719– 28. 30Burisch J, Vardi H, Schwartz D, Friger M, Kiudelis G, Kupčinskas J, et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. Lancet Gastroenterol Hepatol. 2020; 5: 454– 64. 31Akobeng AK, Zhang D, Gordon M, MacDonald JK, Cochrane IBD Group. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2016; 9:CD003715. 32Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev. 2011; 1:CD008414. 33Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO, Cochrane IBD Group. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2003; 4:CD000301. 34Zhulina Y, Udumyan R, Tysk C, Montgomery S, Halfvarson J. The changing face of Crohn's disease: a population-based study of the natural history of Crohn's disease in Örebro, Sweden 1963-2005. Scand J Gastroenterol. 2016; 51: 304– 13. 35Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970-2004). Am J Gastroenterol. 2012; 107: 1693– 701. 36Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000; 231: 38– 45. 37Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99: 956– 63. 38Wintjens D, Bergey F, Saccenti E, Jeuring S, van den Heuvel T, Romberg-Camps M, et al. Disease activity patterns of Crohn's disease in the first ten years after diagnosis in the population-based IBD South Limburg cohort. J Crohns Colitis. 2021; 15: 391– 400. 39Gollop JH, Phillips SF, Melton LJ, Zinsmeister AR. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. Gut. 1988; 29: 49– 56. 40Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut. 2014; 63: 88– 95. 41Bhattacharya A, Rao BB, Koutroubakis IE, Click B, Vargas EJ, Regueiro M, et al. Silent Crohn's disease predicts increased bowel damage during multiyear follow-up: the consequences of under-reporting active inflammation. Inflamm Bowel Dis. 2016; 22: 2665– 71. 42Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. Gut. 2013; 62: 1072– 84. 43Jeuring SFG, van den Heuvel TRA, Liu LYL, Zeegers MP, Hameeteman WH, Romberg-Camps MJ, et al. Improvements in the long-term outcome of Crohn's disease over the past two decades and the relation to changes in medical management: results from the population-based IBDSL cohort. Am J Gastroenterol. 2017; 112: 325– 36. 44Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012; 107: 579– 88. 45Sjöberg D, Holmström T, Larsson M, Nielsen AL, Holmquist L, Ekbom A, et al. Incidence and clinical course of Crohn's disease during the first year – results from the IBD cohort of the Uppsala region (ICURE) of Sweden 2005-2009. J Crohns Colitis. 2014; 8: 215– 22. 46Schoepfer AM, Dehlavi M-A, Fournier N, Safroneeva E, Straumann A, Pittet V, et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013; 108: 1744– 53. quiz 1754. 47Torres J, Burisch J, Riddle M, Dubinsky M, Colombel JF. Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut. 2016; 65: 1061– 9. 48De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015; 385: 1406– 17. 49Rungoe C, Langholz E, Andersson M, Basit S, Nielsen NM, Wohlfahrt J, et al. Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut. 2014; 63: 1607– 16. 50Ramadas AV, Gunesh S, Thomas GAO, Williams GT, Hawthorne AB. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010; 59: 1200– 6. 51Tsai L, Ma C, Dulai PS, Prokop LJ, Eisenstein S, Ramamoorthy SL, et al. Contemporary risk of surgery in patients with Ulcerative colitis and Crohn's disease: a meta-analysis of population-based cohorts. Clin Gastroenterol Hepatol. 2021; 19: 2031– 2045.e11. 52Rönnblom A, Karlbom U. Clinical course of Crohn's disease in a population-based cohort in Uppsala County followed for 10 years. Scand J Gastroenterol. 2020; 55: 1301– 7. 53Rönnblom A, Holmström T, Karlbom U, Tanghöj H, Thörn M, Sjöberg D. Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009(). Scand J Gastroenterol. 2017; 52: 81– 6. 54Lo B, Vester-Andersen MK, Vind I, Prosberg M, Dubinsky M, Siegel CA, et al. Changes in disease behaviour and location in patients with Crohn's disease after seven years of follow-up: a Danish population-based inception cohort. J Crohns Colitis. 2018; 12: 265– 72. 55Solberg IC, Vatn MH, Høie O, Stray N, Sauar J, Jahnsen J, et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007; 5: 1430– 8. 56Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777– 82. 57Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002; 8: 244– 50. 58Ryan JD, Silverberg MS, Xu W, Graff LA, Targownik LE, Walker JR, et al. Predicting complicated Crohn's disease and surgery: phenotypes, genetics, serology and psychological characteristics of a population-based cohort. Aliment Pharmacol Ther. 2013; 38: 274– 83. 59Golovics PA, Lakatos L, Mandel MD, Lovasz BD, Vegh Z, Kurti Z, et al. Prevalence and predictors of hospitalization in Crohn's disease in a prospective population-based inception cohort from 2000-2012. World J Gastroenterol. 2015; 21: 7272– 80. 60Eriksson C, Cao Y, Rundquist S, Zhulina Y, Henriksson I, Montgomery S, et al. Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. Aliment Pharmacol Ther. 2017; 46: 748– 57. 61Leijonmarck CE, Löfberg R, Ost A, Hellers G. Long-term results of ileorectal anastomosis in ulcerative colitis in Stockholm County. Dis Colon Rectum. 1990; 33: 195– 200. 62Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al. Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Inflamm Bowel Dis. 2006; 12: 669– 76. 63Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992; 103: 1444– 51. 64Jeuring SFG, Bours PHA, Zeegers MP, Ambergen TW, van den Heuvel TRA, Romberg-Camps MJL, et al. Disease outcome of Ulcerative colitis in an era of changing treatment strategies: results from the Dutch population-based IBDSL cohort. J Crohns Colitis. 2015; 9: 837– 45. 65Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, et al. Low colectomy rates in Ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007; 132: 507– 15. 66Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009; 44: 431– 40. 67Vester-Andersen MK, Prosberg MV, Jess T, Andersson M, Bengtsson BG, Blixt T, et al. Disease course and surgery rates in inflammatory bowel disease: a population-based, 7-year follow-up study in the era of immunomodulating therapy. Am J Gastroenterol. 2014; 109: 705– 14. 68Rönnblom A, Holmström T, Tanghöj H, Karlbom U, Thörn M, Sjöberg D. Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009. Scand J Gastroenterol. 2016; 51: 1339– 44. 69Lakatos L, Kiss LS, David G, Pandur T, Erdelyi Z, Mester G, et al. Incidence, disease phenotype at diagnosis, and early disease course in inflammatory bowel diseases in Western Hungary, 2002-2006. Inflamm Bowel Dis. 2011; 17: 2558– 65. 70Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013; 19: 1858– 66. 71Monstad IL, Solberg IC, Cvancarova M, Hovde O, Henriksen M, Huppertz-Hauss G, et al. Outcome of Ulcerative colitis 20 years after diagnosis in a prospective population-based inception cohort from south-eastern Norway, the IBSEN study. J Crohns Colitis. 2020; 15: 969– 79. 72Tøttrup A, Erichsen R, Sværke C, Laurberg S, Srensen HT. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open. 2012; 2: 1– 8. 73Sebastian S, Myers S, Argyriou K, Martin G, Los L, Fiske J, et al. Infliximab induction regimens in steroid-refractory acute severe colitis: a multicentre retrospective cohort study with propensity score analysis. Aliment Pharmacol Ther. 2019; 50: 675– 83. 74Ritchie JK, Powell-Tuck J, Lennard-Jones JE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet. 1978; 1: 1140– 3. 75Hendriksen C, Kreiner S, Binder V. Long term prognosis in ulcerative colitis–based on results from a regional patient group from the county of Copenhagen. Gut. 1985; 26: 158– 63. 76Burisch J, Ungaro R, Vind I, Prosberg MV, Bendtsen F, Colombel JF, et al. Proximal disease extension in patients with limited Ulcerative colitis: a Danish population-based inception cohort. J Crohns Colitis. 2017; 11: 1200– 4. 77Höie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al. Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. Am J Gastroenterol. 2007; 102: 1692– 701. 78Roda G, Narula N, Pinotti R, Skamnelos A, Katsanos KH, Ungaro R, et al. Systematic review with meta-analysis: proximal disease extension in limited ulcerative colitis. Aliment Pharmacol Ther. 2017; 45: 1481– 92. 79Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V. Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol. 1996; 31: 260– 6. 80Moum B, Ekbom A, Vatn MH, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol. 1999; 94: 1564– 9. 81Lakatos PL, David G, Pandur T, Erdelyi Z, Mester G, Balogh M, et al. IBD in the elderly population: results from a population-based study in Western Hungary, 1977-2008. J Crohns Colitis. 2011; 5: 5– 13. 82Charpentier C, Salleron J, Savoye G, Fumery M, Merle V, Laberenne JE, et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut. 2014; 63: 423– 32. 83Hochart A, Gower-Rousseau C, Sarter H, Fumery M, Ley D, Spyckerelle C, et al. Ulcerative proctitis is a frequent location of paediatric-onset UC and not a minor disease: a population-based study. Gut. 2017; 66: 1912– 7. 84Størdal K, Jahnsen J, Bentsen BS, Moum B. Pediatric inflammatory bowel disease in southeastern Norway: a five-year follow-up study. Digestion. 2004; 70: 226– 30. 85Jakobsen C, Bartek J, Wewer V, Vind I, Munkholm P, Groen R, et al. Differences in phenotype and disease course in adult and paediatric inflammatory bowel disease-a population-based study. Aliment Pharmacol Ther. 2011; 34: 1217– 24. 86Everhov ÅH, Halfvarson J, Myrelid P, Sachs MC, Nordenvall C, Söderling J, et al. Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden. Gastroenterology. 2018; 154: 518– 528.e15. 87Frøslie KF, Jahnsen J, Moum BA, Vatn MH, IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133: 412– 22. 88Colombel JF, Rutgeerts P, Reinisch W, Esser D, Wang Y, Lang Y, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011; 141: 1194– 201. 89Turner D, Ricciuto A, Lewis A, D'Amico F, Dhaliwal J, Griffiths AM, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021; 160: 1570– 83. 90Mao EJ, Hazlewood GS, Kaplan GG, Peyrin-Biroulet L, Ananthakrishnan AN. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2017; 45: 3– 13. 91Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonnel F, et al. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009–2014. Aliment Pharmacol Ther. 2017; 45: 37– 49. 92Niewiadomski O, Studd C, Hair C, Wilson J, Ding NS, Heerasing N, et al. Prospective population-based cohort of inflammatory bowel disease in the biologics era: disease course and predictors of severity. J Gastroenterol Hepatol. 2015; 30: 1346– 53. 93Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994; 35: 360– 2. 94Jeuring SFG, Biemans VBC, van den Heuvel TRA, Zeegers MP, Hameeteman WH, Romberg-Camps MJL, et al. Corticosteroid sparing in inflammatory bowel disease is more often achieved in the Immunomodulator and biological era-results from the Dutch population-based IBDSL cohort. Am J Gastroenterol. 2018; 113: 384– 95. 95Targownik LE, Nugent Z, Singh H, Bernstein CN. Prevalence of and outcomes associated with corticosteroid prescription in inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20: 622– 30. 96Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, et al. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut. 2020; 69: 274– 82. 97D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat Rev Gastroenterol Hepatol. 2010; 7: 86– 92. 98Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, et al. Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial. Gut. 2014; 63: 1721– 7. 99Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014; 63: 919– 27. 100Colombel J, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2017; 152: 351– 361.e5. 101Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 2019; 13: 144– 64. 102Louis E, Mary JY, Verniermassouille G, Grimaud JC, Bouhnik Y, Laharie D, et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012; 142: 63– 70.e5. 103Maillard MH, Bortolotti M, Vader J-P, Mottet C, Schoepfer A, Gonvers JJ, et al. Appropriateness and long-term discontinuation rate of biological therapies in ulcerative colitis. J Crohns Colitis. 2014; 8: 825– 34. 104Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2013; 30: 67– 72. 105Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020; 14: 4– 22. 106Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, et al. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: current management. J Crohns Colitis. 2017; 11: 769– 84. 107Péntek M, Lakatos PL, Oorsprong T, Gulácsi L, Pavlova M, Groot W, et al. Access to biologicals in Crohn's disease in ten European countries. World J Gastroenterol. 2017; 23: 6294– 305. 108Gulácsi L, Rencz F, Poór G, Szekanecz Z, Brodszky V, Baji P, et al. Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences. Ann Rheum Dis. 2016; 75: 942– 3. 109Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010; 139: 1147– 55. 110Schoepfer A, Bortolotti M, Pittet V, Mottet C, Gonvers JJ, Reich O, et al. The gap between scientific evidence and clinical practice: 5-aminosalicylates are frequently used for the treatment of Crohn's disease. Aliment Pharmacol Ther. 2014; 40: 930– 7. 111Chhaya V, Saxena S, Cecil E, Subramanian V, Curcin V, Majeed A, et al. Steroid dependency and trends in prescribing for inflammatory bowel disease – a 20-year national population-based study. Aliment Pharmacol Ther. 2016; 44: 482– 94. 112Hart A, Ng SC, Watkins J, Paridaens K, Edwards JO, Fullarton JR, et al. The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK clinical practice research datalink. Ann Gastroenterol. 2020; 33: 500– 7. 113Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019; 68: s1– s106. 114Noureldin M, Cohen-Mekelburg S, Mahmood A, Stidham R, Higgins PDR, Govani S, et al. Trends of 5-Aminosalicylate medication use in patients with Crohn disease. Inflamm Bowel Dis. 2020; 27: 516– 21. 115Ma C, Ascoytia C, McCarrier KP, Martin M, Feagan BG, Jairath V. Physicians' perspectives on cost, safety, and perceived efficacy determine Aminosalicylate use in Crohn's disease. Dig Dis Sci. 2018; 63: 2555– 63. 116Klag T, Stange EF, Wehkamp J. Management of Crohn's disease – are guidelines transferred to clinical practice? United Eur Gastroenterol J. 2015; 3: 371– 80. 117Gearry RB, Ajlouni Y, Nandurkar S, Iser JH, Gibson PR. 5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists. Inflamm Bowel Dis. 2007; 13: 1009– 15. 118Wintjens D, Bergey F, Saccenti E, Jeuring S, Romberg-Camps M, Oostenbrug L, et al. OP002 assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn's disease cohort shows a quiescent disease course for a substantial proportion of the population. J Crohns Colitis. 2018; 12: S001– 3. 119Bernstein CN, Longobardi T, Finlayson G, Blanchard JF. Direct medical cost of managing IBD patients: a Canadian population-based study. Inflamm Bowel Dis. 2012; 18: 1498– 508. 120Gisbert JP, Marín AC, Chaparro M. The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2016; 111: 632– 47. 121Pillai N, Dusheiko M, Maillard MH, Rogler G, Brüngger B, Bähler C, et al. The evolution of health care utilisation and costs for inflammatory bowel disease over ten years. J Crohns Colitis. 2019; 13: 744– 54. 122van der Valk ME, Mangen M-JJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, et al. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. Gut. 2014; 63: 72– 9. 123Lo B, Vind I, Vester-Andersen MK, Bendtsen F, Burisch J. Direct and indirect costs of inflammatory bowel disease: ten years of follow-up in a Danish population-based inception cohort. J Crohns Colitis. 2020; 14: 53– 63. 124Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, et al. Direct health care costs of Crohn's disease and Ulcerati